Comparative effects of mesoglycan and ticlopidine treatment on some coagulative parameters in patients with previous ischemic stroke: Results of a randomized controlled trial

Current Therapeutic Research - Clinical and Experimental

Volumn 63, Issue 5, 2002, Pages 337-343

  Orefice, Giuseppe ^a   Brancaccio, Vincenzo ^b   Coppola, Giovanni ^a   Iannaccone, Luigi ^b   Ascione, Salvatore ^a   Manchia, Antonella ^a   Vacca, Giovanni ^a   Morra, Vincenzo Brescia ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

Author keywords

Ischemic stroke; Mesoglycan; Plasma fibrinogen level; Ticlopidine

Indexed keywords

MESOGLYCAN; PROTHROMBIN; TICLOPIDINE;

ARTICLE; BLOOD CLOTTING; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; FEMALE; FIBRINOGEN BLOOD LEVEL; HEART INFARCTION; HUMAN; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

EID: 0036306912     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(02)80037-6     Document Type: Article

References (11)

1. Coagulation-fibrinolysis abnormalities in acute and chronic phases of cerebral thrombosis and embolism
2. Fibrinogen as a risk factor for stroke and myocardial infarction
3. Drugs affecting plasma fibrinogen levels
4. Therapeutic interventions to lower plasma fibrinogen concentration
5. Antithrombotic properties of dermatan sulphate in a rat venous thrombosis model
6. Effect of a single dose of mesoglycan on the human fibrinolytic system, and the profibrinolytic action of nine daily doses
7. Effect of long-term mesoglycan treatment on fibrinogen plasma levels in patients with ischemic cerebrovascular disease
8. How does ticlopidine treatment lower plasma fibrinogen?
9. Effects of diet, drugs, and genes on plasma fibrinogen levels
10. Influence of fibrin, fibrinogen and fibrinogen degradation products on cultured endothelial cells
11. Fibrinogen, fibrin, and fibrin degradation products in relation to atherosclerosis